Fiche société
Sumitomo Pharma America, Inc.
Traitements, essais et publications liés.
Traitements5programmes
Essais2liés
Publications3liées
SourceDBlocale
Traitements
5| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| APL-130277An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease | Parkinson | Phase 3 | À vérifier | United States, Austria, Canada, France, Germany, Italy, Spain, United Kingdom | À vérifier |
| DSP-1083 implantationThe Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female patients in 2 cohorts. This study will be held in approximately 5-8 study sites in United States | Parkinson | Phase 1/2 | À vérifier | United States | À vérifier |
| Sham surgery treatmentThe Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female patients in 2 cohorts. This study will be held in approximately 5-8 study sites in United States | Parkinson | Phase 1/2 | À vérifier | United States | À vérifier |
| APL-130277An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease | Parkinson | Phase 3 | À vérifier | United States, Austria, Canada, France, Germany, Italy, Spain, United Kingdom | À vérifier |
| DSP-1083 implantationThe Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female patients in 2 cohorts. This study will be held in approximately 5-8 study sites in United States | Parkinson | Phase 1/2 | À vérifier | United States | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| DSP-1083 implantation | Parkinson | Phase 1/2 | NCT06753331 | A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease | RECRUITING |
| APL-130277 | Parkinson | Phase 3 | NCT02542696 | Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease | COMPLETED |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| APL-130277 | Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes. | Parkinsonism & related disorders | ||
| APL-130277 | Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease. | Parkinsonism & related disorders | ||
| APL-130277 | Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes. | Journal of comparative effectiveness research |